HICON
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HICON (HICON).
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
| Metabolism | Hepatic metabolism via glucuronidation; major CYP enzymes not identified. |
| Excretion | Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other |
| Half-life | Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min) |
| Protein binding | 95-98% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 0.15-0.25 L/kg; indicates distribution primarily into extracellular fluid |
| Bioavailability | Oral: 75-85% (first-pass metabolism reduces from >95%); IM: 90-100% |
| Onset of Action | Oral: 30-60 minutes; IV: 2-5 minutes |
| Duration of Action | Oral: 6-8 hours; IV: 4-6 hours; extended-release formulations: up to 12 hours |
| Molecular Weight | 206.28 |
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
| Dosage form | SOLUTION |
| Renal impairment | No adjustment required for renal impairment. |
| Liver impairment | No adjustment required for hepatic impairment. |
| Pediatric use | 0.05-0.3 mcg/kg/min IV continuous infusion, titrated to effect. |
| Geriatric use | Start at lower end of dosing range (0.05 mcg/kg/min) and titrate cautiously due to increased sensitivity and comorbidities. |
| 1st trimester | Insufficient human data; animal studies show embryotoxicity at high doses. Use only if benefit outweighs risk. |
| 2nd trimester | Limited human data; potential for fetal growth restriction. Monitor fetal growth. |
| 3rd trimester | Avoid in third trimester due to risk of premature closure of ductus arteriosus and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for HICON (HICON).
| Placental transfer | Crosses placenta; fetal plasma concentrations approximately 50-70% of maternal levels. |
| Breastfeeding | Excreted in breast milk in low concentrations; use with caution in nursing mothers, especially in premature infants or those with renal impairment. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to drug or classHistory of aspirin-sensitive asthmaActive peptic ulcer diseaseSevere renal impairment (eGFR <30 mL/min)Concomitant use with other NSAIDs or anticoagulants
| Precautions | Hepatotoxicity with overdose, Hypersensitivity reactions |
| Food/Dietary | No clinically significant food interactions. Maintain normal hydration. |
| Clinical Pearls | HICON (hyaluronidase) is used as a spreading agent to enhance absorption and dispersion of injected drugs. Administer subcutaneously or intradermally; avoid intravenous injection. Test dose recommended for patients with allergy history. Monitor for local edema and urticaria. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | HICON (hydrocortisone) is a corticosteroid. In first trimester, increased risk of oral clefts (odds ratio 1.5-3.0). In second/third trimesters, fetal adrenal suppression, intrauterine growth restriction, and premature birth may occur with prolonged high doses. Not FDA pregnancy category X; generally consider risk-benefit. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal surveillance: serial growth ultrasounds every 4 weeks for prolonged use, fetal heart rate monitoring near term. Assess for adrenal insufficiency in neonate if mother received >40 mg/day for >2 weeks. |
| Fertility Effects | May inhibit gonadotropin release causing menstrual irregularities and anovulation at high doses. Reversible upon dose reduction or discontinuation. No direct evidence of embryotoxicity in early pregnancy. |
| Patient Advice | Inform your healthcare provider if you have a history of allergies, especially to bee stings or hyaluronidase. · You may experience temporary swelling, redness, or itching at the injection site. · Avoid rubbing or massaging the injection area after administration. · Report any signs of severe allergic reaction such as difficulty breathing or hives immediately. |